Latest / CME Outfitters Medical Education / Staying Current – Navigating the Latest Advances in PrEP Options
Transcript
- 0:01SPEAKER_03: Hello and welcome.
- 0:03SPEAKER_03: On behalf of CME Outfitters, I would like to welcome and thank you for joining us for this CMEO SNAC titled Staying Current, Navigating the Latest Advances in Prep Options.
- 0:16SPEAKER_03: This program has been supported by an independent educational grant from Gilead Sciences, Incorporated.
- 0:24SPEAKER_03: Today's activity may include discussions of products or devices that are not currently labeled for use by the US FDA.
- 0:33SPEAKER_03: As a reminder, this is a global program.
- 0:36SPEAKER_03: Indications and availability vary by regulatory authority.
- 0:41SPEAKER_03: Clinicians should consult local guidance when confirming approved PrEP options.
- 0:47SPEAKER_03: Thank you for joining us today.
- 0:49SPEAKER_03: I'm Dr.
- 0:50SPEAKER_03: Christina Madison, founder and CEO at the Public Health Pharmacist, and I'm delighted to be joined by an incredible panel for this discussion.
- 1:00SPEAKER_03: They will provide their global and regional insights as we begin to navigate through new territory.
- 1:07SPEAKER_03: I'll start with Dr.
- 1:09SPEAKER_03: Orkin and allow each faculty to introduce themselves.
- 1:14SPEAKER_03: Dr.
- 1:15SPEAKER_03: Orkin.
- 1:16SPEAKER_01: Hello, everybody.
- 1:17SPEAKER_01: My name is Chloe Orkin.
- 1:19SPEAKER_01: I'm Professor of Infection and Inequities at Queen Mary University of London and a clinician at Bart's Health NHS Trust in London.
- 1:28SPEAKER_00: Hi everyone, I'm Sunil Solomon.
- 1:31SPEAKER_00: I'm a professor of medicine and epidemiology at the Johns Hopkins University School of Medicine in Baltimore, USA.
- 1:37SPEAKER_02: Hi everyone, I'm Bahuma Tutanji.
- 1:40SPEAKER_02: I am an assistant professor of infectious diseases based at Emory University in Atlanta.
- 1:45SPEAKER_02: I am an HIV physician practicing within the Emory healthcare system.
- 1:52SPEAKER_03: Our learning objective for today's program is to evaluate the latest data on prep options, including efficacy, safety, mechanism of action, and mode of administration.
- 2:05SPEAKER_03: So let's begin by navigating this changing route.
- 2:09SPEAKER_03: Dr.
- 2:10SPEAKER_03: Solomon?
- 2:12SPEAKER_00: Sure, I think most of us remember the late 1980s when we did not even have highly active antiretroviral therapy, but and behavioral intervention such as condomuse and was primarily the only thing we had.
- 2:26SPEAKER_00: But that being said, I think condomuse is something that's very underrated.
- 2:30SPEAKER_00: It actually is extremely efficacious if used properly.
- 2:33SPEAKER_00: But we also recognize that people's needs have evolved and each person is different and choices are always great.
- 2:39SPEAKER_00: So over the past two decades, we've had a couple of breakthroughs.
- 2:43SPEAKER_00: So we have treatment as prevention, which is the untransmissible undetectable is equal to untransmittable, but really the prevention toolbox has expanded.
- 2:52SPEAKER_00: So what started off as daily oral prep, which is one regimen, has we now have two different regimens, and we've transitioned to on-demand oral prep as well as we have injectable prep, and we have two different combinations of injectable prep that are currently approved by the FDA, uh injectable cabotegrave and injectable Lenacapavir.
- 3:15SPEAKER_01: And I think it would be great now at this point to really bring us back to clinical practice after that amazing introduction from Dr.
- 3:23SPEAKER_01: Sullivan.
- 3:23SPEAKER_01: So Dr.
- 3:24SPEAKER_01: Madison is going to start us off by revisiting how we talk about PrEP and PEP in the clinic.
- 3:30SPEAKER_01: And that's something that still confuses many people and also people at risk of HIV.
- 3:37SPEAKER_03: So here's our reminders and level setting for today's presentation.
- 3:42SPEAKER_03: We know that PrEP is proactive if we start it before an exposure and take it ongoingly.
- 3:50SPEAKER_03: We know that PEP is reactive, which can be started within 72 hours and continued for 28 days.
- 3:58SPEAKER_03: Both require a prescription, PEP is definitely more urgent, and PrEP can be routine.
- 4:06SPEAKER_03: When taken as prescribed, we know that PrEP reduces HIV risk by up to 99%.
- 4:13SPEAKER_03: There's so few things in this world that have that level of certainty.
- 4:18SPEAKER_03: Now that we've distinguished between PrEP and PEP, let's look at the PrEP options themselves.
- 4:27SPEAKER_03: Dr.
- 4:27SPEAKER_03: Solomon, can you walk us through the current PrEP formulations and how their differences shape clinical decisions?
- 4:35SPEAKER_03: I'd like to emphasize again for our global audience to check your local guidance.
- 4:42SPEAKER_00: There are a couple of different options as I mentioned already.
- 4:45SPEAKER_00: So we have two oral options, which is essentially a combination of tenophival DF and tenophivir allofinemide, which is T DAF, both in combination with MCitabine, which is FTC.
- 4:57SPEAKER_00: So these are both oral daily medications.
- 5:00SPEAKER_00: So TDF FTC has like a broader recommendation.
- 5:04SPEAKER_00: It's recommended by the FDA, EMA, WHO and several guidelines for sexual transmission, both uh unprotected anal intercourse as well as unprotected vaginal intercourse.
- 5:14SPEAKER_00: Uh FTAF, which is TAF and FTC, has a similar indication except it's currently not indicated for the prevention of HIV transmission in unprotected vaginal intercourse.
- 5:27SPEAKER_00: We also have two new long-acting formulations.
- 5:31SPEAKER_00: One is cabotegravir and the other one is lenicapovir.
- 5:34SPEAKER_00: Both of them are injectables.
- 5:38SPEAKER_00: Cabotegra is once every two months, and Lenicapovir is once every six months.
- 5:42SPEAKER_00: Both of them have an indication for the prevention of sexual transmission of HIV.
- 5:48SPEAKER_00: They're both approved by the US FDA.
- 5:50SPEAKER_00: There also is the depivory and vaginal ring, which is a monthly ring that is inserted by women, which is also approved by the EMA and the WHO, but it's not currently approved by the FDA.
- 6:01SPEAKER_00: The one thing I do want to point out is there is guidance that all these products can be used, especially FTDF, for the prevention of HIV acquisition by injection drug use.
- 6:13SPEAKER_00: But as of now, there are currently no drugs that have an FDA indication for the prevention of HIV acquisition by injection drug use.
- 6:54SPEAKER_03: I really appreciate you saying that, Dr.
- 6:56SPEAKER_03: Tatanji, because I do think that, yes, it's exciting that we have these injectable products, but we do have to remember that oral prep still remains a foundation for the global community.
- 7:09SPEAKER_03: Dr.
- 7:10SPEAKER_03: Orkin, let's start with the oral prep options.
- 7:13SPEAKER_03: Since for many clinicians, this is the most familiar entry point before expanding the PrEP toolkit.
- 7:21SPEAKER_01: Yeah, absolutely.
- 7:22SPEAKER_01: And as Dr.
- 7:23SPEAKER_01: Solomon has already said, um, we do have two uh potentially daily oral prep options, which can also be used on demand.
- 7:31SPEAKER_01: But uh let's focus on TDF and FTC first, why they use rate of your treatment.
- 7:37SPEAKER_01: And it's been approved for PrEP a long time ago in 2012.
- 7:40SPEAKER_01: Um TAF FTC, more recently approved for PrEP 2019, but not indicated for people uh at risk based on receptive vaginal sex.
- 7:51SPEAKER_01: And the important thing to say here is that both are highly effective when taken as prescribed.
- 7:57SPEAKER_01: You can see 99% effective when taken as prescribed.
- 8:01SPEAKER_01: There are some key safety differences with TDF FTC, renal function monitoring is important, and there can be small reversible uh BMD changes.
- 8:12SPEAKER_01: But with TAP FTC, renal and bone biomarker effects are generally smaller compared with TDF.
- 8:18SPEAKER_01: So I guess the bottom line here is that both require adherence to oral therapies daily.
- 8:23SPEAKER_01: Um and therefore the fit for these regimens really comes down to what is right for the person in terms of their preference, their routine, and their context.
- 8:38SPEAKER_03: I couldn't agree with you more.
- 8:40SPEAKER_03: We really have to meet our patients where they are and make sure that we're doing our prescribing based off of shared clinical decision making.
- 8:49SPEAKER_03: We've reviewed the oral options, but access depends on geography.
- 8:54SPEAKER_03: Regulatory approvals and prescribing limitations vary widely.
- 8:58SPEAKER_03: So let's talk about the global landscape and what that looks like.
- 9:03SPEAKER_01: I think one of the important things is that while oral prep has an efficacy rate of more than 90%, as close to 99%, when it's used in what we call the real world, the effectiveness drops to 60%.
- 9:18SPEAKER_01: Um and this is a huge, a huge issue.
- 9:23SPEAKER_01: Um, you know, it can't be overstated uh how important this is.
- 9:27SPEAKER_01: Um and we just have to remember that the outcomes don't equate to clinical trial efficacy.
- 9:37SPEAKER_01: And I think we have to think about this is not across the board.
- 9:41SPEAKER_01: There are some populations that find it a lot easier to take oral therapy, uh, and we often see that adherence is worse uh in the studies, uh including cisgendered women, uh, regarding uh adherence to oral therapy.
- 9:55SPEAKER_01: We see it in socioeconomically disadvantaged people, we see it in younger people, and we may see it people or see it in people who are struggling uh with substance use.
- 10:05SPEAKER_01: So I think you know this is a very, very important consideration.
- 10:09SPEAKER_02: And to add to that, I think that it's also important going back to the point of the regulatory issues and the barriers of access to a variety of prep options continues to be an issue in countries where you may not have access to lung acting therapy and where it's stigmatizing to be on a daily preventative medication for HIV.
- 10:34SPEAKER_02: Because, particularly taking the context of sub-Saharan Africa, a lot of people still associate being on prep to being a reflection of how sexually promiscuous a woman may be.
- 10:46SPEAKER_02: And really being able to have those other options that are discrete, that are easy to be adherent to is absolutely key in these populations.
- 10:56SPEAKER_02: So again, going back to Chloe's point that in real life scenarios you get lower efficacy.
- 11:03SPEAKER_02: That may be because people are still struggling with issues around stigma, feeling they need to hide their medications, maybe not going to the prep clinic at the frequency they need to go to to pick up their medications, impacting adherence.
- 11:17SPEAKER_02: When you have adherence to oral prep, it's very highly efficacious at 99%.
- 11:22SPEAKER_02: But the moment that adherence drops off and becomes more patchy, then we start getting to the 60% levels that we see in real life.
- 11:31SPEAKER_02: And we there's a lot of room for improvement.
- 11:33SPEAKER_02: And that would come with addressing these barriers that I have expanded on.
- 11:38SPEAKER_00: And the only thing I would probably add on is really tailoring prep to the individual, and it's a constantly evolving process because someone may start off with daily oral prep and then they may want 2-1-1 prep, then they may go back.
- 11:52SPEAKER_00: So really having that conversation and that decision on prep being made between the provider and the client, depending on what's available in each country within the regulatory environment, is a critical way to try and improve effectiveness.
- 12:06SPEAKER_03: I think that was truly illustrated very well.
- 12:09SPEAKER_03: Uh, a few years ago, there was a poster that was published at Croix looking at dynamic choice and those sentiments that you've all mentioned were were a part of that.
- 12:20SPEAKER_03: Uh, when folks had the ability to change, um, they definitely uh were more likely to stay adherent to their therapy.
- 12:29SPEAKER_03: So I really appreciate the point about understanding and and determining what folks want based off of their lived experience, and that that could change um based off of what's currently going on in their life.
- 12:43SPEAKER_03: So at this point, um I wanted to uh switch a little bit and talk about um access.
- 12:49SPEAKER_03: Um and obviously we know that access is not only one part of the equation.
- 12:54SPEAKER_03: So, Dr.
- 12:55SPEAKER_03: Orkin, can you speak to this uh and and and how that could obviously uh impact our real world efficacy, as you mentioned before?
- 13:06SPEAKER_01: Yeah, I think that just the issue is once again that even when prep is available, real world outcomes don't mirror the clinical trial efficacy.
- 13:13SPEAKER_01: And the daily oral prep definitely will exceed 90% efficacy when taken as prescribed, but the real world evidence efficacy is lower.
- 13:22SPEAKER_01: And this really does center on adherence.
- 13:25SPEAKER_01: And I think we often think about you know challenges in terms of access purely in terms of accessing services, um, but you know, not knowing where to get it, or sort of prep literacy as we can call it, but in reality, um taking daily pills just does not fit everyone's lifestyle and isn't isn't possible for many people.
- 13:48SPEAKER_03: Dr.
- 13:49SPEAKER_03: Sullivan, would you like to expand further?
- 13:52SPEAKER_03: And then others, would you like to talk about expansion into your clinical practice?
- 13:57SPEAKER_03: Could you perhaps discuss the new data out of Croy in regards to long-acting injectables?
- 14:04SPEAKER_00: Sure, maybe we'll start with cabotagra.
- 14:06SPEAKER_00: So I think most of you are aware cabotagra is a long-acting injectable.
- 14:11SPEAKER_00: It was approved by the FDA in December 2021 for PrEP in adults and adolescents.
- 14:17SPEAKER_00: Its mechanism of action is like it really prevents the integration of HIV with the host DNA, and it's given as a gluteal intramuscular injection.
- 14:26SPEAKER_00: You need uh the initial injections are one month apart, but following that it's every two months.
- 14:31SPEAKER_00: I think what was really fascinating in Croy 2025 was really the real-world cohorts that presented data from the opera and the trio health courts, which was about 1,300 people who were on long-acting cabinet grave here for PrEP.
- 14:45SPEAKER_00: And I think what they really saw was like 85% of them were injecting on time, there was 69% on-time injection.
- 14:52SPEAKER_00: And it really was, I think, to the point that Bahuma mentioned earlier, was like something that was discrete with an injection every two months.
- 14:58SPEAKER_00: So there really wasn't a lot of stigma around this, and they actually reported reductions in stigma.
- 15:04SPEAKER_00: So overall, it really is a safe, uh tolerable, injectable study, definitely has more data available on real-world use compared to lacapavir, which has improved much more recently.
- 15:15SPEAKER_00: But I think one of the challenges is integrate, especially outside of the US, remains remains your staple first-line regimen.
- 15:23SPEAKER_00: Even in the US it is, but when you go to the PEPFAR programs, they generally just have one regimen where most people are started on, which is a combination of tenophravir, lamovidine, and dolutegra.
- 15:34SPEAKER_00: So if you have breakthrough infections and you have insta resistance being transmitted from cab or tegravir, it could be challenging for first-line regimens.
- 15:42SPEAKER_00: And that's something we are monitoring.
- 15:44SPEAKER_00: I think the scientific community is monitoring closely, is surveilling for INST resistance among the CAB breakthrough infections.
- 15:52SPEAKER_00: Uh, but most of this data really comes from the HPTN and HPTNO83 and HPT and 084 trials, which really inform the FDA uh approval of PrEP.
- 16:04SPEAKER_02: Yeah, and I would like to add that we have actually seen um just how impactful having the long-acting injectable carbotegrave has been as a PrEP option for our uh client population.
- 16:17SPEAKER_02: Previously, uh, we do have a uh we have a program within our healthcare system that rapidly enrolls people in into prep programs, people who are um desire who desire PrEP or who are eligible for PrEP.
- 16:31SPEAKER_02: And previously, when the only thing we had available to offer were the oral options, we frequently had lots of African-American women decline to be on PrEP.
- 16:42SPEAKER_02: And since we've had carbotech revere as part of our toolkit, a lot of our clients are now a lot more willing to have the conversation, again, because it's discreet.
- 16:52SPEAKER_02: They don't feel that they have to address the issues around stigma, and they also like the convenience of not having to take a pill every day.
- 17:00SPEAKER_02: So this already is allowing us uh to be able to get more people uh connected to PrEP care, and particularly among populations that have traditionally not been the ones that have had the best access uh to PrEP in the United States.
- 17:16SPEAKER_02: We know that optake for PrEP is pretty low in African American women, whereas they are one of the target groups that have the highest uh rates of new HIV infections within the context of the US.
- 17:31SPEAKER_03: Thank you very much, Dr.
- 17:32SPEAKER_03: Titanji, for bringing that up.
- 17:34SPEAKER_03: Uh it's something that I'm personally uh very passionate about as far as getting access uh specifically for African-American women around PrEP.
- 17:42SPEAKER_03: And I do think that having these long-acting options has really changed the narrative around uh showing that you know that population has options that are able to overcome some of the uh possible uh issues around stigma and and maybe not thinking, oh, that that's not for me, just because of the fact that we know that a lot of the oral medications have been heavily marketed towards other groups in the past.
- 18:12SPEAKER_03: So, Dr.
- 18:12SPEAKER_03: Orkin, uh, can you dive a little further into summarizing some of the key findings?
- 18:19SPEAKER_03: Um, and then obviously I would love to have uh Dr.
- 18:21SPEAKER_03: Tatanji Wei in as well, uh, if you could expand upon uh further data around the uh cabote revere efficacy and safety data.
- 18:31SPEAKER_01: Sure, I'd love to do that.
- 18:32SPEAKER_01: But I think before I do that, I just might say that my experience in the UK really chimes with what both of you are saying in an interesting way, because we don't have access to uh cabote revere.
- 18:43SPEAKER_01: Well, we we we're starting to.
- 18:45SPEAKER_01: Um it's been approved, but we're just starting to use it.
- 18:48SPEAKER_01: So we don't have lots of people on it yet.
- 18:50SPEAKER_01: But interestingly, we are doing the purpose five study, which is the NanoCappa VS 6 monthly injectable study for UK and France.
- 18:58SPEAKER_01: What we noticed is that women came forward, cisgender women came forward for the first time.
- 19:03SPEAKER_01: We have women that we've not been able to engage in PrEP, they did want it.
- 19:08SPEAKER_01: It's not that they didn't understand that they needed it, they didn't want oral therapy.
- 19:12SPEAKER_01: So it's fascinating to see how when you actually give an offer that is a wanted offer, suddenly um it's taken up.
- 19:21SPEAKER_01: So it was really fascinating uh for us to see that.
- 19:25SPEAKER_01: Um, but going back uh to cabote, so uh as Dr.
- 19:29SPEAKER_01: Solomon mentioned, there are two large studies, uh randomized studies, which have underpinned the development of cabotegra, namely the HB TNO83 study, which was a large study of about 4,500 people.
- 19:42SPEAKER_01: And the participants were cisgender men who have sex with men and transgender women who have sex with men.
- 19:47SPEAKER_01: And it was done in a number of countries.
- 19:50SPEAKER_01: Um, and HB TNO84, a slightly smaller study, 3,200 participants.
- 19:56SPEAKER_01: Um, and this study was uh people that were assigned female sex at birth in seven countries in sub-Saharan Africa.
- 20:02SPEAKER_01: And in both of the studies, there was a study design which compared cabite ropeverine two monthly in a double blind, double dummy fashion, and there were non-inferior uh active controlled studies, which meant that the participants either received pills uh plus an injection placebo or cavitegrave injections plus uh pills placebo and and the tablets were TDF FTC.
- 20:29SPEAKER_01: So TDF FTC was compared against cavitegoviral or pivotine, but the participants really had to be committed because they had to take a placebo of an alternate placebo.
- 20:39SPEAKER_01: And what was found in the HPTNO83 study is that cavitate reduced the HIV incidence by 66% compared with daily TDF FTC.
- 20:49SPEAKER_01: So very, very significant results meeting criteria for superiority.
- 20:55SPEAKER_01: And uh in the HPT and O84 study, similar findings, an 88% reduction in HIV incidence compared with TDF and FTC, once again, uh evidencing superiority, and the adherence was much, much, much, much, much better uh in both studies uh versus uh all TDF FTC.
- 21:15SPEAKER_01: And the injection site reactions uh are as expected in the Cavitegovia as treatment program.
- 21:21SPEAKER_01: They tend to last uh between a median three to seven days, and they tend to be uh largely grade one and two, they go away quite quickly.
- 21:29SPEAKER_01: Um so I think those are the most important uh findings to report from those two studies.
- 21:36SPEAKER_02: I think that the only thing I would add to what uh Chloe has so uh very clearly and brilliantly summarized is one of the most exciting things about the carbotegraphy data is that we have robust data from cisgender women in sub-Saharan Africa.
- 21:54SPEAKER_02: A lot of the early uh prep studies were primarily focused on other uh risk groups.
- 22:00SPEAKER_02: In European countries or higher income settings, notably men who have sex with men.
- 22:06SPEAKER_02: So this again, you know, emphasizes the fact that when you have options that are adapted to what women want or what a particular population wants, you get not only adherence, you get also to show that uh that intervention is effective.
- 22:25SPEAKER_02: But I would also go back to the access issues we continue to see in sub-Saharan Africa to emphasize that while we have these data that show that it is robust, it is effective in this particular population, a lot of women in these settings continue not to have access to this particular intervention because there's still issues and barriers in terms of approvals locally, as well as being able to make these medications available to the communities that want them and need them.
- 22:58SPEAKER_03: Dr.
- 22:58SPEAKER_03: Solomon, can you walk us through the highlights here specifically for Linux Haposphere?
- 23:04SPEAKER_00: Wait, I think Linu Cap away really is like the newest kid on the block for long-acting prep.
- 23:09SPEAKER_00: It was approved by the FDA in June 2025, really based on the data coming out of purpose one and purpose two.
- 23:16SPEAKER_00: So both those trials were actually halted by the DSMB for efficacy.
- 23:19SPEAKER_00: Um, I did not think in my lifetime I would ever see a product that was 100% efficacious, and that's what the finding was for purpose one, and where amongst this gender women in Africa, there were zero new infections in the Lenacap of Iran.
- 23:34SPEAKER_00: And it was superior to oral FTDF.
- 23:37SPEAKER_00: So the design really was comparing it to a background incidence, and so it met the primary endpoint criteria.
- 23:43SPEAKER_00: Uh, I think what is also interesting with the whole purpose program is there's also a purpose three, purpose four, and a purpose five, which uh Dr.
- 23:50SPEAKER_00: Orkin talked about.
- 23:51SPEAKER_00: So purpose four really is looking at um the acceptability and pharmacokinetics of lenacapavir among people who inject drugs in the US.
- 24:01SPEAKER_00: And I the reason I point that out is because in terms of routes of administration, there were additional routes in addition to the abdominal area that were shown to be favorable for injections of lenacapavir, including the thighs.
- 24:14SPEAKER_00: And so we are using alternative routes for injection subcutaneously.
- 24:18SPEAKER_00: And so it does expand um the options and the feasibility of actually using it uh in clinical practice, but it also lends itself to could we deliver this on vans, could we deliver this in people's houses?
- 24:30SPEAKER_00: And so it's really opening up avenues uh to improve access to Lenicapavir.
- 24:37SPEAKER_02: Within our uh clinic, we actually just had uh our first uh Lenicapavir uh client user.
- 24:44SPEAKER_02: So that's very exciting.
- 24:45SPEAKER_02: In the US, depending on where you are located, of course, there are issues around insurance and coverage, which again is another barrier to accessing uh treatment.
- 24:55SPEAKER_02: But it's very, very exciting to have this option because just the added convenience of being able to only need the intervention twice a year and having that level of efficacy is something that I think, even with the way in which we've seen the demographic shifts in terms of demand with uh carbotagrave here, we are going to see a lot more African American women engaging with prep care uh because when we have Lena Capravir more widely available, it's just such a transformative option to be able to offer to people.
- 25:31SPEAKER_01: I'm gonna make a more sort of uh study-related point, uh, and that is that I'm just really glad that Dr.
- 25:39SPEAKER_01: Solomon pointed out uh the difference in study design between HPT and 083 and 084 and the purpose studies because trials, because um the the cavitate rare studies were compared against oral therapy, oral prep, whereas the lens studies were compared against background incidents.
- 26:00SPEAKER_01: So it's important that one can't cross-compare the studies directly because they are fundamentally different in their study design.
- 26:06SPEAKER_01: They are both very effective, um, incredible, incredible improvements on oral prep.
- 26:11SPEAKER_01: And I think that is, you know, fundamentally important to say.
- 26:15SPEAKER_01: What I can say from my experience of the 18 people that are taking Lenin in our study is that they were, as you say, they were clamoring for it.
- 26:24SPEAKER_01: The exact people that we've been working with for years and doing surveys around hypothetical interest came forward as they said they would, um, and have remained engaged uh and still receiving their injections, several injections along.
- 26:38SPEAKER_01: So it's really positive uh what we've seen.
- 26:41SPEAKER_03: So moving on to uh some of the efficacy and safety data, uh Dr.
- 26:46SPEAKER_03: Orkin, Dr.
- 26:47SPEAKER_03: Tatanji, uh what stands out for you from these data?
- 26:52SPEAKER_01: Well, for me, I think it's just that the the population of of purpose in purpose two has expanded the population from purpose one.
- 26:59SPEAKER_01: It's in more countries, it's in six countries.
- 27:01SPEAKER_01: The efficacy is really robust across different populations.
- 27:05SPEAKER_01: And just again, the adherence and retention is so high.
- 27:09SPEAKER_01: Um, and you know, the injections are absolutely acceptable to the participants from from on the basis of this study.
- 27:16SPEAKER_01: Uh, and adherence is super high and really not comparable, um, particularly um in uh the purpose one study uh to uh oral prep.
- 27:29SPEAKER_02: Yeah, and I will again reiterate that it was really nice to see that purpose one focused on recruiting cisgender women in sub-Saharan Africa, a population that has not always been the one that's been prioritized in these sorts of clinical trials.
- 27:46SPEAKER_02: And it was able to uh we were able to see that the discontinuation rates were really low in Purpose One, and the safety data was really robust, and of course the intervention was highly efficacious.
- 28:00SPEAKER_02: And we know that that is the the target group that still uh represents um the most vulnerable group in terms of the numbers of new infections that are reported every year in that part of the world.
- 28:11SPEAKER_02: And I think that what we should take from this study is not only the fact that we've been able to demonstrate that the intervention is efficacious, but continue to leverage it as a way of advocating to actually getting these interventions widely available uh to people uh in sub-Saharan Africa, notably cisgender women who continue to be one of the most impacted uh groups with by HIV.
- 28:38SPEAKER_02: And I would uh close uh my point by saying that for the first time, with these options for prevention, we really have tools that can effectively interrupt HIV transmission.
- 28:50SPEAKER_02: And that is the way in which we end the HIV epidemic, is by making sure that we're utilizing these tools to their maximal benefit and reducing the numbers of new HIV infections that we're seeing globally.
- 29:05SPEAKER_00: And Christina, if I may just add, I think the one thing we should point out is there were some adverse events, but most of them were injection site reactions.
- 29:12SPEAKER_00: Uh but yes, they're common, they happen in quite a few people, but uh less than 1% of the participants, actually 0.2% in purpose one and about 1.2% in purpose two, actually stopped the lanocaffapirate injections due to these injection site reactions.
- 29:26SPEAKER_00: Well, yes, it is great, but there are some injection site reactions your patients are going to complain about.
- 29:32SPEAKER_00: But remind them that it's efficacious and very few people actually ended up discontinuing this the medic study, the medication due to these injection side reactions.
- 29:42SPEAKER_03: Yeah, I think that's a really great point uh because again, we know that all medications potentially have the risk of having an adverse effect.
- 29:50SPEAKER_03: And so being upfront with the patient uh I think is really important, uh especially when we talk about the nodules that could be potentially developed after uh you know injection and the fact that they they can last for a while.
- 30:05SPEAKER_03: Um, it could be months um before you see some you know disillusion of that.
- 30:10SPEAKER_03: And so I think it's just really important to talk with them.
- 30:13SPEAKER_03: Um I mean, obviously, risk versus benefit, the benefits definitely outweigh uh, you know, the tiny knowledge that you may get uh at the injection site.
- 30:22SPEAKER_03: So I I think a lot of patients are are definitely um more likely to stay on that therapy because of the fact that uh it it wasn't enough for them to need to discontinue.
- 30:32SPEAKER_03: So I appreciate that.
- 30:33SPEAKER_03: Uh moving on, I I did want to ask you, Dr.
- 30:36SPEAKER_03: Solomon, if you could walk us through the current regulatory landscape as to where these long-acting injectable options are approved and what that means for implementation on the ground.
- 30:49SPEAKER_00: So I think as I mentioned earlier, CAB was approved in 2021 by the FD and Lena Kapavir in 2025.
- 30:54SPEAKER_00: So CAB obviously has a lot more approvals.
- 30:57SPEAKER_00: They have about 30 approvals covering 62 countries with one pending, and the most recent was Vietnam that was added to the list in 2025.
- 31:06SPEAKER_00: Lena Kapavir has about 15 approvals and eight pending.
- 31:09SPEAKER_00: And as Dr.
- 31:10SPEAKER_00: Orkin already mentioned, it's much more challenging to get long-acting therapies in the UK.
- 31:14SPEAKER_00: Cabote Gavir is available via purpose fire, they have access to Lena Kapavir.
- 31:19SPEAKER_00: So I think what that really means is that's like a constantly evolving landscape of what is available in your country.
- 31:26SPEAKER_00: So looking at local regulatory authorities or resources like Prep Watch to tell you what is available in your particular setting will help you make an informed decision with your patient who's sitting in front of you.
- 31:40SPEAKER_00: What is the best medication for you given what we have here today?
- 31:43SPEAKER_00: But that being said, I think regulatory approvals is one thing, access is a different thing.
- 31:49SPEAKER_00: So while these regulatory approvals are happening, it's also important for programs without thinking about access, whether it's programs such as PEPFAR or the Global Fund or local government programs, like who are the right populations, how do we roll it out?
- 32:02SPEAKER_00: So I think those conversations need to be happening as these regulatory approvals and processes are in place.
- 32:11SPEAKER_03: We know that many of our primary care providers may feel unprepared to prescribe or to discuss PrEP options.
- 32:20SPEAKER_03: Uh, I wanted to take a moment to discuss some clinical pearls that we can extend to our global audience to make them feel maybe a bit more comfortable.
- 32:30SPEAKER_02: Yeah, you raise a very important point, which is, I think, one of the biggest barriers to PrEP, is that we don't offer it enough.
- 32:37SPEAKER_02: And that's because this notion that in order to be able to offer PrEP, you should be someone who is an HIV care provider or trained in infectious diseases.
- 32:48SPEAKER_02: I try to emphasize to all clinicians that if you are a clinician and you are in contact with patients, that you are someone who should feel empowered to be able to offer PrEP because it is a preventative modality that practitioners should be uh familiar with and should be comfortable with offering.
- 33:09SPEAKER_02: And I think that the first point of conversation is talk getting practitioners to be able to even have the conversation or think about who is eligible for PrEP.
- 33:18SPEAKER_02: The person who is eligible for pre-PREP is anyone who has an HIV negative test and who wants PrEP.
- 33:24SPEAKER_02: You shouldn't uh require to that the person prove that they have a certain risk profile for you to have the conversation about PrEP.
- 33:33SPEAKER_02: And I think that there's so many missed opportunities when we interact with individuals in clinical practice where we fail to be able to have the conversation about PrEP because they're coming in for something else and you've not thought about it.
- 33:49SPEAKER_02: And I think that in order to get to that point, is continuing to uh remind uh providers that HIV is still very real, and more importantly, that we have tools that can help prevent uh HIV acquisition, and that thirdly, these tools are safe and highly efficacious, and lastly, that they can prescribe it without necessarily having formal treatment as HIV physicians or as infectious diseases experts.
- 34:17SPEAKER_03: Prep care is not specialty care, it's everybody care.
- 34:20SPEAKER_03: And I feel we all deserve to have a sex life that is free from feeling like we may have, you know, been exposed to something because we're already protected.
- 34:32SPEAKER_03: Dr.
- 34:33SPEAKER_03: Orkin.
- 34:34SPEAKER_01: Yeah, I so agree with you.
- 34:35SPEAKER_01: And I feel really frustrated at times because in the UK, there's a lot of teaching of medical students, you know, and an ethos in the hospital, make every contact count.
- 34:46SPEAKER_01: We call it MEC training.
- 34:48SPEAKER_01: Um, and that means if you're seeing someone, you should ask them about smoking, you should measure their blood pressure.
- 34:54SPEAKER_01: No matter what you're doing, you should try and use it as an opportunity for prevention to improve people's health.
- 35:00SPEAKER_01: And somehow PrEP, which is such a simple intervention, just does not form part of this conversation.
- 35:07SPEAKER_01: And I think this is just because we're not comfortable.
- 35:09SPEAKER_01: We don't want to raise the idea of sex.
- 35:12SPEAKER_01: You know, we would rather talk about measuring someone's blood pressure than this absolutely life-saving intervention.
- 35:17SPEAKER_01: And it just hasn't made the cut in the way that it should do as being part of everyday conversations.
- 35:23SPEAKER_01: You know, and I think this is a real issue because in reality, it's a drug that can be easily prescribed or prep, you know, and you know, it you need some monitoring, aren'tal monitoring, but actually it's a very low-risk intervention.
- 35:37SPEAKER_01: And the injectables, again, are very tolerable, but people've got to take responsibility uh for having that conversation.
- 35:45SPEAKER_01: And it's about how do we do that.
- 35:48SPEAKER_03: Did you want to talk a little bit about the comorbidities um and any of the follow-up that may be necessary?
- 35:56SPEAKER_00: So I think what as as as Dr.
- 35:57SPEAKER_00: Ark and others mentioned, the the biggest challenge really is getting them to be comfortable.
- 36:02SPEAKER_00: I think we we we notice very often when I talk to people outside of the HIV field, sex is not a topic they're comfortable asking people about.
- 36:09SPEAKER_00: So that's the first thing that has to happen.
- 36:11SPEAKER_00: But I there are comorbidities, and we also have to figure out, like I said, like what's people's plans, like how often do they want to come in?
- 36:18SPEAKER_00: Do they want medications delivered to them, which happens in many countries across the world.
- 36:22SPEAKER_00: Um, there are some toxicities to the bone and renal toxicities that people need to talk about.
- 36:27SPEAKER_00: But those really can be addressed through educational programs like this.
- 36:31SPEAKER_00: I think the challenge really with PCPs and getting them ready is to really get them to feel comfortable asking the person in front of them, how's your sex life?
- 36:39SPEAKER_00: And I think that really is the biggest challenge we're facing.
- 36:44SPEAKER_01: Yeah, I couldn't agree more.
- 36:45SPEAKER_01: And you know, the the algorithms, you know, digital pathways in the UK where PrEP is provided, you click a link, you get assessed, you know, according to your complexity, you given PrEP, you have your blood tests.
- 36:57SPEAKER_01: Um it's not complex.
- 37:00SPEAKER_01: It's just that we have our own barriers as healthcare providers about initiating these conversations.
- 37:06SPEAKER_01: And we need to be honest that we'd rather talk about smoking than about PrEP.
- 37:10SPEAKER_01: And that is that has a consequence to individuals who then end up acquiring HIV because of our our discomfort.
- 37:17SPEAKER_00: It's gonna be an interesting time to see how these different products are used.
- 37:21SPEAKER_03: Yeah, can we uh maybe expand into uh staying with this concept of eligibility?
- 37:28SPEAKER_03: Um, we have uh some considerations, some baseline considerations that I'd love for you to discuss with us, Dr.
- 37:34SPEAKER_03: Solomon.
- 37:35SPEAKER_00: Sure.
- 37:35SPEAKER_00: I think given that PrEP is to prevent HIV acquisition, probably the most important thing you want to do is ensure that whoever you are screening for PrEP is confirmed as not being infected with HIV, either with four-generation antigen antibody tests.
- 37:50SPEAKER_00: And if there's recent exposure, consider an HIV RNA.
- 37:53SPEAKER_00: You want to make sure the renal function is normal because some regimens have more favorable safety profiles, as Dr.
- 38:00SPEAKER_00: Orkin mentioned.
- 38:01SPEAKER_00: You also want to look at age and pregnancy because, based on available data, available guidelines, you need to figure out what works for the particular person sitting in front of you.
- 38:12SPEAKER_00: Um, there are barriers I think that that everyone has talked about, including stigma, patient uh level barriers, logistical barriers.
- 38:20SPEAKER_00: So trying to figure out which is the right regimen uh in the selection is something that to consider.
- 38:26SPEAKER_00: The other thing I would probably include here is also looking at hepatitis B surface antigen.
- 38:31SPEAKER_00: I think that's something that's very important to look at because two of these regimens, FTDF and FDAF, if you're giving it in people who are co-infected with hepatitis B, there is a risk of or hepatic flare when you stop it.
- 38:46SPEAKER_00: So you want to be very careful about starting and stopping uh FTDF and FDAF and people who are co-infected versus people who are getting on CAB or lenacapovir, there is no action on hepatitis B.
- 38:59SPEAKER_00: And so you probably want to monitor hepatitis B infections separately in these individuals.
- 39:05SPEAKER_03: So the prevention pipeline continues to evolve.
- 39:07SPEAKER_03: So, Dr.
- 39:08SPEAKER_03: Orkin, what's on the horizon?
- 39:10SPEAKER_03: What should we be looking forward to?
- 39:13SPEAKER_01: Well, at Croy last year, there was literally, you could have heard a pin drop.
- 39:19SPEAKER_01: They told us that there may be the possibility based on phase one data of once yearly I am dosing polenic at mea as PrEP, therefore even further reducing the number of injections.
- 39:32SPEAKER_01: So that was a wow moment.
- 39:34SPEAKER_01: Um, let's hope it happens.
- 39:36SPEAKER_01: And then the other option is MKA527, uh NRTTI, which is uh once monthly oral option.
- 39:43SPEAKER_01: Again, for not everybody wants injections.
- 39:46SPEAKER_01: So actually giving this flexibility is really important.
- 39:49SPEAKER_01: It's much lower frequency, and it is a really viable alternative, uh, very interesting as well.
- 39:56SPEAKER_01: So both of those things, super exciting.
- 40:00SPEAKER_03: There are a range of patient education tools, many available on CME Outfitters website.
- 40:06SPEAKER_03: Uh, Dr.
- 40:07SPEAKER_03: Titanji, uh, what tools do you think we could use to help uh frame the basics?
- 40:12SPEAKER_02: Yeah, I always like to say that, you know, when I'm approaching a new client and offering prep, is that my job is to offer you options and you choose what option best fits your life.
- 40:25SPEAKER_03: So to close, we want to leave you with three practical goals you can take back to your setting.
- 40:32SPEAKER_03: Uh the first, uh, because again, we want to make sure we we have SMART goals here that are specific, measurable, attainable, relevant, and timely.
- 40:43SPEAKER_03: So the first is use a prep option counseling aid to initiate prep discussions and support shared clinical decision making in your choice or practice team in the next 30 days.
- 40:56SPEAKER_03: Implement a standardized prep initiation approach for both daily oral prep and long-acting options, including appropriate HIV testing and symptom assessment per local guidance within the next 60 days, and then to develop and apply a clinical workflow to support ongoing prep use, including plans for missed doses or injections with oral prep bridging when appropriate, patient follow-up reminders, use of patient education materials, and discussion of clinic resources to address cost and access barriers within the next 60 to 90 days.
- 41:33SPEAKER_03: I would like to personally thank our faculty for sharing their insights and thank you to our audience for joining us today.
- 41:41SPEAKER_03: We encourage you to explore the additional resources linked with this activity and continue the conversation in your own practice.
- 41:49SPEAKER_03: We would also like to invite you to visit the CME Outfitter Infectious Disease Hub, which includes free evidence-based resources for both healthcare professionals and patients.
- 42:00SPEAKER_03: These tools are designed to support practical implementation.
- 42:04SPEAKER_03: As a reminder, this activity is part of a broader HIV prevention education series.
- 42:10SPEAKER_03: We encourage you to explore these programs and to continue building on today's discussion.
- 42:15SPEAKER_03: Before we wrap up, just a quick reminder that to receive CME or CE credit for this activity, you will need to complete the post test and evaluation online.
- 42:26SPEAKER_03: Once completed, you'll be able to download and print your certificate immediately.